IP Group's portfolio company Istesso reports mixed results from RA drug trial
Why we think this is neutral
The RNS provides a balanced update on the Phase 2b study of Istesso's drug candidate leramistat for the treatment of rheumatoid arthritis. While the study did not meet the primary endpoint, it demonstrated positive results in key secondary endpoints related to bone erosions, disability and fatigue. The findings support further evaluation of leramistat's potential, and Istesso is sufficiently funded to conduct additional studies. Overall, the news is neither overwhelmingly positive nor negative, warranting a neutral sentiment score.
Key Points
- Leramistat did not meet the primary endpoint of improvements in ACR20 versus placebo
- However, the drug showed statistically significant reductions in bone erosions, as well as improvements in disability and fatigue
- These results support further evaluation of leramistat's potential to promote adaptive tissue repair in RA and other chronic conditions
- Istesso is sufficiently funded to conduct additional studies
Summary
IP Group's portfolio company Istesso has provided an update on the Phase 2b study of its drug candidate leramistat for the treatment of rheumatoid arthritis (RA). Although the study did not meet the primary endpoint of improvements in ACR20 versus placebo, leramistat demonstrated statistically significant reductions in the key secondary endpoint of bone erosions, as well as improvements in disability and fatigue. These findings support further evaluation of leramistat's potential to promote adaptive tissue repair in RA and other chronic conditions. Istesso is sufficiently funded to conduct additional studies.